Tetrabenazine-induced miR-34a-5p suppresses the tumorigenicity of radioresistant colorectal cancer by inhibiting M2 macrophage polarization Authors: Dong Hyeon Lee, Hyun Jeong Seok, Jae Yeon Choi, Junhye Kwon, Ui Sup Shin, In Hwa Bae Published: 2025 ABSTRACT AbstractBackgroundRadiotherapy is a very common treatment method for various cancers; however, it is not effective for patients with radioresistance. Accordingly, the discovery of drugs for patients with radioresistance cancer is critical. This study used a Food and Drug Administration (FDA)-approved drug library to identify candidate drugs for the treatment of radioresistant colorectal cancer (CRC). This approach to drug development benefits from its low cost and time requirements and can lead to rapid clinical translation.MethodsDrugs that suppress radioresistance in CRC cells were screened. Effects of candidate drugs on cell viability and the expression of epithelial-mesenchymal transition (EMT)-related factors were evaluated through using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and quantitative real-time PCR (qRT-PCR). The effects of TBZ, identified as a candidate, on radioresistant CRC cells and organoids were evaluated using MTT, qRT-PCR, western blotting, migration, and invasion assays. Factors mediating the suppressive effects of TBZ on tumorigenicity, including the roles of Snail and the p53-miR-34a-5p axis, were evaluated using chromatin immunoprecipitation (ChIP), promoter luciferase, western blotting, qRT-PCR, and dual luciferase assays. Expression of M2 markers in THP-1-derived macrophages was confirmed by qRT-PCR.ResultsTBZ, an anti-hyperkinesia drug, was identified as a candidate agent able to reduce tumorigenicity. In radioresistant CRC cells, treatment with TBZ downregulated EMT-related factors and decreased cell migratory ability and invasiveness via reductions in Snail expression through p53-induced miR-34a-5p. Cell migration and invasion assays confirmed that TBZ had greater inhibitory effects on the migration and invasiveness of radioresistant CRC cells than those of 5-FU. Furthermore, TBZ-induced miR-34a-5p reduced M2 macrophage polarization and IL-10 secretion, thereby reducing the tumorigenicity of radioresistant CRC cells. These findings were verified using samples from patients with CRC.ConclusionsTBZ reduces tumorigenicity via the regulation of the p53-miR-34a-5p/Snail axis in radioresistant CRC cells and suppression of M2 macrophage polarization, decreasing IL-10 secretion. Our study provides insight into drug repurposing by revealing the mechanism by which TBZ, an FDA-approved drug, reduces tumorigenicity through communication between radioresistant CRC cells and macrophages.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12964-025-02595-0.Keywords: Radioresistant colorectal cancer, Tetrabenazine, M2 macrophage polarization, MiR-34a-5p Introduction Colorectal cancer (CRC) is the third most common cancer worldwide and a major cause of cancer-related death [1]. Locally advanced rectal cancer (LARC) is treated with short-course radiotherapy (SCRT) and the standard treatment, neoadjuvant chemoradiotherapy (nCRT). Both modalities effectively reduce the risk of local recurrence and improve patient survival [2]. However, approximately 20–40% of patients with LARC experience a poor or incomplete pathologic response to nCRT [3]. This inherent or acquired radioresistance is directly associated with a worse prognosis, increasing the rates of local recurrence and distant metastasis and ultimately reducing overall survival [4–6]. Furthermore, radiotherapy has many side effects, especially for patients with radioresistant CRC [7–9]. Therefore, the development of novel therapeutic strategies to overcome radioresistance is necessary to improve patient outcomes. Radioresistance is driven by complex interactions among multiple cells within the tumor microenvironment (TME). In particular, hypoxia, the complex community of cells within solid tumors, including tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs), and the aberrant overactivation of oncogenic signaling pathways, such as PI3K/AKT/mTOR, are key factors in this resistance [10, 11]. Despite extensive research, strategies for overcoming radioresistance are not clearly established. Ultimately, strategies that simultaneously target signaling pathways within the tumor and TME may be useful. Utilizing drug repurposing to overcome radioresistance is a highly practical and efficient strategy, significantly reducing the time and cost required for drug development. Therefore, this study adopted a drug repurposing approach based on an FDA-approved drug library with established safety profiles to ensure rapid clinical applications. Recent reports have highlighted microRNAs (miRNAs) as key determinants of anticancer therapeutic efficacy [12–16]. Secreted miRNAs contribute to intercellular communication within the TME [17–20] and are involved in regulating M2 macrophage polarization, a hallmark of the immunosuppressive microenvironment [21–23]. Furthermore, miRNA expression is regulated by upstream transcription factors, such as p53, a key regulator of miR-34a [24], ultimately suppressing the expression of the epithelial-mesenchymal transition (EMT)-related factor Snail [25, 26]. Based on these insights, we hypothesized that TBZ could inhibit radioresistance. We evaluated the effects of TBZ on malignancy as well as the roles the p53–miR-34a-5p/Snail axis, macrophage-secreted miR-34a-5p, and M2 macrophage polarization. We conducted cellular, patient-derived organoid (PDO), and animal experiments to verify the signaling pathways by which TBZ exerts effects in tumors and macrophages, suggesting that TBZ is a promising therapeutic strategy for radioresistant CRC. Materials and methods Chemicals A library of FDA-approved drugs was purchased from Enzo Life Sciences (SCREEN-WELL FDA-approved drug library V2, BML-2843–0100, NY, USA). 5-FU was obtained from Sigma Aldrich (MO, USA). TBZ was purchased from Selleckchem (TX, USA). Human recombinant IL-10 was obtained from R&D Systems (MN, USA). Drug screening Radioresistant CRC cells HCT116R and SW480R were treated with FDA-approved drugs (10 µM) for 48 h and harvested. The efficacy of the drugs was screened by comparing the mRNA expression of EMT markers (Snail, N-cadherin, and Zeb1) and cell viability through qRT-PCR and MTT assays, respectively. Organoid culture Patients with clinical stage T3N + received neoadjuvant chemoradiotherapy (NCRT) and were evaluated using MRI and PET scans before and after treatment. After NCRT, patients were classified into radiosensitive and radioresistant responses based on tumor regression grade (TRG). The patient-derived organoid was embedded in matrigel (Corning, NY USA) and cultured in DMEM/F12 culture media (Corning, NY USA) contained B27 (Gibco, NY, USA), N-acetyl cysteine (United States Pharmacopeia, MD, USA), human epidermal growth factor (BioVision, CA, USA), human Noggin (Peprotech, NJ, USA), A83-01 (BioVision, CA, USA), and gastrin (Sigma-Aldrich, MO, USA). Y-27632 (BioVision, CA, USA) was added to the culture medium only during the first 2–3 days of culture after cell dissociation. Animal experiments HCT116 (1 × 107) cells were injected to the flank of five-week-old BALB/c female nude mice. When the tumor volume reached 100 mm3, TBZ (18 mg/kg) was injected intraperitoneally five times a week. Tumor volume was measured using calipers. Mice were sacrificed 31 days after cell injection. The experiment was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Korea Institute of Radiological & Medical Sciences (Kirams2023-0134). Cell lines and cell culture HCT116, SW480, and THP-1 cells were purchased from Korean Cell Line Bank (KCLB, Seoul, Korea). HCT116, SW480 and THP-1 cells were cultured in RPMI 1640 media (Corning, NY, USA). All media contain 10% Fetal Bovine Serum (FBS), (Corning, NY, USA) and 1% penicillin streptomycin (Corning, NY, USA). Cells were cultured in an incubator at 5% CO2 and 37℃. Irradiation Cells were irradiated with 137Cs γ-rays source by Biobeam8000 (GSM, Kaufering, Germany) with a dose rate of 5 Gy. Western blot analysis Proteins were extracted with lysis buffer containing protease inhibitors (Roche, Basel, Switzerland) and phosphatase inhibitor cocktail tablet (Roche, Basel, Switzerland). The extracted proteins were separated by SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membrane (Millipore corporation, MA, USA). Primary antibodies were incubated overnight at 4℃ and secondary antibodies were incubated at room temperature for 1 h. After washing the membrane with TBS-T, detection was performed using ECL solution (Thermo Fisher Scientific, MA, USA) and the Amersham Imager 600 system (GE HeathCare, IL, USA). Information on the antibodies used is provided in Supplementary Table S1. Transwell migration and invasion assays In the migration assay, cells were seeded after coating 0.2% gelatin on 8 µm pore transwells (Corning, NY, USA). In the invasion assay, cells were seeded after coating Matrigel (Corning, NY, USA) on 8 µm pore transwells (Corning, NY, USA). In both assays, the lower chamber was filled with medium, fixed with methanol after 16 h, and stained with crystal violet. Clonogenic assay HCT116 (1 × 103, 2.5 × 104, 3.5 × 104, 5 × 104, and 7.5 × 104 cells/dish) and SW480 cells (5 × 103, 3.0 × 104, 4.5 × 104, 6 × 104, and 9 × 104 cells/dish) were seeded at various cell numbers in 60 mm dishes, respectively. After 2 weeks, the colonies were fixed with methanol and stained with crystal violet. The stained colonies were counted and expressed graphically. Proliferation assay HCT116 and SW480 cells were seeded in 96-well plates and cultured for 48 h. MTT (Sigma-Aldrich, MO, USA) solution was then added, and the cells were incubated for 4 h. Subsequently, DMSO (Sigma-Aldrich, MO, USA) was added, and the absorbance was measured at 570 nm. MiRNA mimic, plasmid DNAs, and transfection miR-34a-5p mimic, miR-34a-5p inhibitor were synthesized by Genolution Inc. (Seoul, Korea). p53 and Snail overexpression vectors were synthesized from cDNA and inserted into the pCMV-Tag2B vector. PLKOp53 was kindly provided by J. H. Jeong (Division of Radiation Biomedical Research, Korea Institute of Radiological & Medical Sciences, Republic of Korea). MiRNA and plasmid were transfected using lipofectamine 2000 reagent (Invitrogen, MA, USA). Promoter assay Promoter constructs were formed using the miR-34a promoter containing a p53 binding site in pGL3-basic vector (Promega, WI, USA). Luciferase activity was measured after 48 h by co-transfection with the miR-34a promoter construct, pRL-CMV-Renilla plasmid (Promega, Madison, USA), and p53 overexpression vector. Luciferase activity was assessed using the dual-luciferase reporter assay system (Promega, WI, USA) and normalized to Renilla luciferase activity. All luciferase activities were represented graphically. Chromatin immunoprecipitation (ChIP) assay After combination p53 overexpression and/or TBZ treatment for 48 h, cells were cross-linked with 1% formaldehyde for 10 min at room temperature. Cells were lysed with TE buffer containing protease inhibitor and 0.5% NP-40 followed by sonication was performed. Use seahorse beads (Santa Cruz, TX, USA) and anti-p53 (Santa Cruz, TX, USA) antibody overnight after then wash 3 times with TE buffer containing 500 mM NaCl. After elution with 0.5 mM NaHCO3 and 1% SDS buffer, the DNA was purified using a DNA purification kit (Bioneer, Dajeon, Korea), and then PCR was performed. Dual-luciferase reporter assay The miR-34a-5p binding site of Snail 3'UTR was inserted into the pmiRGLO vector (Promega, WI, USA). After seeding cells in 24 wells plate, reporter plasmids or miR-34a-5p mimic, and pRL-CMV-Renilla plasmids were co-transfected for 48 h. Luciferase activity was measured using a dual-luciferase reporter assay system (Promega, WI, USA) and normalized to Renilla luciferase activity. The luciferase activity was represented graphically. Total RNA extraction and Real-time qRT-PCR assay Total RNA was isolated from cells and plasma using Trizol reagent (Qiagen, Hilden, Germany). Complementary DNA (cDNA) was synthesized with the SensiFAST™ cDNA synthesis Kit (Bioline, OH, USA) and Mir-X™ miRNA First-Strand Synthesis Kit (Takara, Kusatsu, Japan). Real-time PCR was performed using Power SYBR™ Green PCR Master Mix (Applied Biosystems, MA, USA). Clinical specimens Tissues and plasma from CRC patients were Institutional Review Board (IRB) approved in Korea Institute of Radiological and Medical Science (KIRAMS-2021–04-002–001). The biological specimens used in this study were received by the Korea Institute of Radiological and Medical Sciences (KIRAMS), Radiation Biobank (KRB) in Republic of Korea (KRB-2021-I002, KRB-2023-I001). The biopsies of cancer patients used in this study were provided by the Radiation Tissue Resources Bank of Korea Cancer Center Hospital (TB-2021–02). Hematoxylin & Eosin (H&E) and Immunohistochemistry (IHC) staining Colorectal patient tissues were fixed with 4% paraformaldehyde for 24 h and then embedded in paraffin. The paraffin-embedded sections were deparaffinized, rehydrated, and stained with Hematoxylin (Dako, CA, USA) and Eosin (Thermo Fisher Scientific, MA, USA). For immunohistochemistry (IHC) staining, paraffin sections were treated with the target retrieval solution (DAKO, CA, USA), and endogenous peroxidase was blocked with BLOXALL endogenous blocking solution (Vector Laboratories, CA, USA). The primary antibody was applied. After incubation with a biotinylated secondary antibody and DAB staining was used for signal visualization. The stained sections were analyzed using cellSens software (Olympus, Tokyo, Japan). The antibodies used are shown in Supplementary Table S1. ELISA The level of IL-10 in THP-1-derived macrophage was analyzed using the human IL-10 quantikine ELISA kit (R&D systems, MN, USA), following the manufacturer’s instructions. The absorbance was measured at 450 nm. Availability of data and materials Kaplan-Meier analyses of survival in cancers were performed by the open sources KM Plotter (http://www.kmplot.com). MiRNA target prediction was provided by miRDB (http://www.mirdb.org), miRmap (https://mirmap.ezlab.org) and TargetScan (http://www.targetscan.org). Statistical analysis GraphPad software was used for all data analysis. All data are indicated as mean ± SD. Statistical calculations were indicated with student’s t test or ANOVA. P < 0.05 was considered significant. Results Screened TBZ suppresses viability, mesenchymal traits, migratory ability, and invasiveness in radioresistant CRC cells More than 70% of patients with CRC respond poorly to radiotherapy [27]. Radioresistance is one of the major factors limiting the effectiveness of radiotherapy [5]. Therefore, we established CRC cells for the identification of candidate drugs to overcome radioresistance using an FDA-approved drug library. First, radiation-resistant HCT116R and SW480R cells were constructed by exposing CRC cells, HCT116 and SW480, to 5 Gy of radiation 15 times for a total dose of 75 Gy [28]. To verify the constructed radioresistant CRC cells, the parental and radioresistant cells were treated with various doses of radiation and radiosensitivity was then evaluated using a clonogenic assay. The radioresistant HCT116R and SW480R CRC cells showed significantly higher survival rates in a radiation dose-dependent manner than those of the parental cells (Fig. S1A-B). After the subcutaneous injection of HCT116 and HCT116R cells into mice, the tumor volume in the HCT116 group tended to be lower than that in the HCT116R group (Fig. S1C). These findings verified at the cellular level and in vivo the successful establishment of radioresistant CRC cells. We screened drugs that suppress cell viability and the expression of the EMT markers Snail, N-cadherin, and Zeb1 in radioresistant CRC cells using an FDA-approved drug library (Fig. S2A). First, we treated radioresistant HCT116R and SW480R cells with various FDA-approved drugs to determine their effects on cell survival. Five drugs (#A01, #A03, #A09, #A10, and #A11) resulted in a decrease in cell viability in radioresistant HCT116R and SW480R CRC cells (Fig. S2B). We then administered each of the five candidate drugs to the two radioresistant CRC cell lines to identify those that significantly reduce the mRNA expression levels of EMT markers, which are key factors in cancer malignancy. Based on this analysis, Tetrabenazine (TBZ, #A01) was identified as a candidate (Fig. S2C). TBZ is used to treat various hyperkinetic movement disorders by reversibly depleting monoamines via the inhibition of vesicular monoamine transporter type 2 [29]. We investigated viability in two radioresistant CRC cell lines after treatment with TBZ at various concentrations. TBZ decreased cell viability in a dose-dependent manner in parental and radioresistant CRC cells. The viability of radioresistant CRC cells was higher than that of parental cells when treated with TBZ (Fig. 1A). For further verification, we treated organoids derived from patients with radiosensitive and radioresistant CRC with TBZ. The viability of radioresistant organoids was higher than that of radiosensitive organoids, consistent with the results obtained at the cellular level (Fig. 1B). PDO, which closely mimic cancer cells in vivo, are frequently used as a model in studies of CRC to overcome the limitations of existing 2D cell culture studies [30, 31]. TBZ inhibited the survival and tumorigenicity of radioresistant CRC cells. A Parental (P) and radioresistant (R) CRC cells HCT116 and SW480 were treated with various concentrations (0, 50, 75, 100, 150, and 200 µM) of TBZ, respectively, and cell viability was determined by MTT assay. B Cell viability after various concentration treatment of TBZ (0, 75, and 150 µM) in organoids derived from radiosensitive (RS) and radioresistant (RR) CRC patients was determined by MTT assay. (F–H) After TBZ (75 µM) treatment in two parental and radioresistant CRC cells HCT116 and SW480, the expression of EMT-related proteins (C), cell mobility (D), and invasiveness (E) were confirmed using western blotting analysis, transwell migration assay, and transwell invasion assay, respectively (Scale bar, 100 µm). β-Actin was used as a loading control. HCT116P and HCT116R cells (1 × 107 cells/mouse) were injected subcutaneously into the flanks of Balb/c nude mice, respectively (Parental cells: NC, n = 4; TBZ, n = 4; Radioresistant cells: NC, n = 4; TBZ, n = 4). After cell transplantation, mice were intraperitoneally injected with TBZ (18 mg/kg) for 10 times over 2 weeks and sacrificed on day 31. F-G The tumor size of mice injected with each indicated cell was compared according to whether or not TBZ was treated. H The average body weight change of each group of mice is shown graphically. The data are expressed as the mean ± SD after triplicate experiments. *P < 0.05, **P < 0.005, and ***P < 0.0005. Student’s t-test or ANOVA The effect of TBZ on tumorigenicity was further evaluated in radioresistant CRC cells. The expression levels of EMT-related marker proteins, which were higher in HCT116R and SW480R cells than in parental cells, decreased in response to TBZ treatment. Among EMT-related marker proteins, Snail was significantly downregulated by TBZ (Fig. 1C). The higher migration and invasive abilities in HCT116R and SW480R cells than in parental cells were also attenuated by TBZ (Fig. 1D-E). These results demonstrate that TBZ may exert anticancer effects by suppressing the tumorigenic potential of radioresistant CRC cells. Based on the results of in vitro assay, we evaluated the effectiveness of TBZ against radioresistant CRC in vivo. Xenograft mice implanted with HCT116 and HCT116R cells and injected with TBZ intraperitoneally showed a decrease in tumor size compared with that in the untreated group. In particular, we confirmed that the TBZ-induced tumor size reduction was greater in mice injected with HCT116R cells than in mice injected with HCT116 cells (Fig. 1F-G). There were no significant changes in the body weight of mice in each group after TBZ treatment, indicating a lack of toxicity (Fig. 1H). In summary, these results showed that TBZ can reduce the growth of radioresistant CRC. Furthermore, we examined the effects of co-treatment with radiation and/or TBZ on cell viability and tumorigenicity. In HCT116R and SW480R cells, the dose-dependent decrease in cell viability was greater in the radiation and TBZ combination group than in the radiation-only group (Fig. S3A). Furthermore, reductions in the expression levels of EMT-related marker proteins, cell migration, and invasive characteristics were greater in the radiation and TBZ combination group than in the radiation-only group (Fig. S3B-D). In mice injected subcutaneously with HCT116R cells, the tumor volumes in the radiation and TBZ combination group were significantly lower than those in the radiation-only group (Fig. S3E). These results demonstrate that TBZ can enhance the radiosensitivity of radioresistant CRC and reduce tumor growth. In patients with radioresistant CRC, radiotherapy not only has minimal effects but also causes side effects, such as fecal incontinence, anal sphincter dysfunction, changes in bowel frequency, and diarrhea, which diminish quality of life and increase the risk of serious complications [32, 33]. This emphasizes the urgent need to develop effective alternatives to radiotherapy in the treatment of patients with radioresistant CRC. This study provides evidence for the value of TBZ as a treatment for patients with radioresistant CRC. Additional experiments were focused on confirming and validating the anticancer efficacy and mechanism of action of TBZ in radioresistant CRC cell lines and animal models. Comparison of the effects of 5-FU and TBZ on the tumorigenic phenotype in radioresistant CRC cells 5-FU is widely used in the treatment of CRC; however, it is not effective against cancer stem cells (CSCs), which limits its clinical use [34, 35]. Various strategies, including combination therapies, have been evaluated to overcome this issue; however, it has not been completely resolved. We compared the effects of TBZ and the conventional treatment 5-FU on tumorigenicity. First, we examined cell viability after 48 h of treatment with various concentrations of 5-FU in HCT116R and SW480R (Fig. 2A). Cell viability was evaluated after treating radioresistant CRC cells with 5-FU and TBZ for 72 h. The reduction in cell viability was greater for TBZ than for 5-FU (Fig. 2B). In HCT116R and SW480R cells, the TBZ treatment group showed greater decreases in mobility and invasiveness than those in the 5-FU treatment group (Fig. 2C-D). These results suggest that TBZ can be used as a treatment for radioresistant CRC, with greater effects on tumorigenicity than those of 5-FU. However, further validation is needed. TBZ is more effective than 5-fluorouracil in reducing tumorigenic phenotype. A To evaluate the anticancer drug sensitivity of 5-fluorouracil (5-FU) in two radioresistant CRC cells, HCT116 and SW480, cell viability was determined by MTT assay at various concentrations (0, 1, 5, 10, and 20 µM). B The relative cell viability between TBZ (200 µM) and 5-FU (20 µM) in HCT116R and SW480R cells was compared by MTT assay. C-D After treating HCT116R and SW480R cells with TBZ (75 µM) and 5-FU (5 µM), migratory ability (C) and invasiveness (D) were determined by transwell migration assay and invasion assay, respectively (Scale bar, 100 µm). The data are expressed as the mean ± SD after triplicate experiments. *P < 0.05, **P < 0.005, and ***P < 0.0005. Student’s t-test or ANOVA TBZ inhibits tumorigenicity by suppressing snail expression As shown in Fig. 1C, the expression of Snail was dramatically reduced by TBZ treatment at the cellular level. Therefore, we further verified the relationship between TBZ, Snail expression, and tumorigenicity. We confirmed that the TBZ-induced decreases in the expression levels of EMT-related markers, cell migration, and invasive properties in HCT116R and SW480R cells were attenuated when Snail was overexpressed (Fig. 3A-C). In mice injected with HCT116 and HCT116R cells, the mRNA expression levels of Snail in tumor tissues obtained after TBZ treatment were lower than those in the control group (Fig. 3D-E). In particular, Snail mRNA expression was dramatically reduced after TBZ treatment in the HCT116R group (Fig. 3E). TBZ inhibits tumorigenicity by reducing the expression of Snail. A-C The expression of EMT-related proteins (A), cell mobility (B), and invasiveness (C) in response to TBZ treatment or Snail overexpression in HCT116R and SW480R cells were determined using western blotting analysis, transwell migration assay, and invasion assay, respectively (Scale bar, 100 µm). β-Actin was used as a loading control. D-E HCT116P and HCT116R cells (1 × 107 cells/mouse) were injected subcutaneously into the flanks of Balb/c nude mice, respectively (Parental cells: NC, n = 4; TBZ, n = 4; Radioresistant cells: NC, n = 4; TBZ, n = 4). After cell transplantation, mice were intraperitoneally injected with TBZ (18 mg/kg) for 10 times over 2 weeks and sacrificed on day 31. D-ESnail mRNA levels in tumor tissues of mice injected with HCT116 and HCT116R cells were detected by qRT-PCR. qRT-PCR values were normalized by GAPDH. F Relative Snail mRNA levels between radiosensitive (RS) organoids and radioresistant (RR) organoids were confirmed by qRT-PCR. G The correlation between the survival rate of rectal adenocarcinoma patients and Snail levels was shown using a Kaplan–Meier plotter. The data are presented as the mean ± SD after triplicate experiments. *P < 0.05, **P < 0.005, and ***P < 0.0005. Student’s t-test or ANOVA In analyses using PDOs, we found that Snail expression was higher in organoids derived from tumors of patients with radioresistant CRC than in those derived from patients with radiosensitive CRC (Fig. 3F). As shown in KM plots, higher Snail expression was associated with a worse prognosis in patients with rectum adenocarcinoma (Fig. 3G). In addition, higher Snail expression was negatively correlated with prognosis in various other cancers (Fig. S4). These results suggest that TBZ suppresses the expression of Snail, which is highly expressed in radioresistant CRC, thereby reducing tumorigenicity. miR-34a-5p targets Snail and is induced by TBZ, which is associated with a good prognosis MicroRNAs are involved in various biological processes, including cancer development and progression [36]. Therefore, we hypothesized that miRNAs are involved in the signal transduction mechanism underlying TBZ-induced radioresistance inhibition. First, we identified candidate miRNAs targeting Snail using the miRNA target prediction sites miRDB and miRmap. Among these candidates, we screened for miRNAs whose expression was increased by TBZ (Fig. 4A). Candidate miRNAs were upregulated upon TBZ treatment in HCT116R and SW480R cells (Fig. 4B-C). The miR-34a-5p, which suppresses the expression of Snail and is up-regulated by TBZ, was identified. A Venn diagram is presented to identify miR-34a-5p, which is up-regulated by TBZ, after screening candidate miRNAs targeting Snail through two miRNA prediction sites, including miRDB (http://www.mirdb.org) and miRmap (https://mirmap.ezlab.org). B-C The miRNA levels of miR-34a-5p, miR-449a, and miR-449b-5p were determined using qRT-PCR after treatment with TBZ (75 µM) in HCT116R (B) and SW480R (C) cells. D-F After transfecting various miRNA mimics (miR-34a-5p, miR-449a, and miR-449b-5p) in HCT116R and SW480R cells, the expression levels of Snail mRNA (D) and protein (E–F) were detected by qRT-PCR and western blotting analysis, respectively. qRT-PCR values were normalized by GAPDH. β-Actin was used as a loading control. G After co-transfection of firefly luciferase construct containing wild- (WT) or mutant-type (MT) target regions of the 3'UTR of Snail predicted to bind miR-34a-5p and miR-34a-5p overexpression, the binding of the two factors was confirmed by luciferase assay. H Expression of miR-34a-5p in parental and radioresistant CRC cells HCT116 and SW480 cells was confirmed by qRT-PCR. I The miR-34a-5p levels were determined by qRT-PCR after treatment with TBZ (75 µM) in RR organoids. J The relative levels of miR-34a-5p between RS and RR organoids were determined by qRT-PCR. K-L miR-34a-5p levels were detected by qRT-PCR in plasma (normal: n = 24; CRC patients: n = 43) (K) and tissues (normal: n = 22; CRC patients: n = 23) (L) of normal and CRC patients. All miRNA qRT-PCR values were normalized by U6. The data are expressed as the mean ± SD after triplicate experiments. *P < 0.05, **P < 0.005, and ***P < 0.0005. Student’s t-test After overexpressing each miRNA in HCT116R and SW480R cells, we evaluated the mRNA and protein expression of Snail. miR-34a-5p resulted in the greatest reductions in the mRNA and protein expression levels of Snail (Fig. 4D-F). To determine whether Snail is a direct target of miR-34a-5p, we constructed 3'UTR reporter plasmids containing Snail 3'UTR with wild-type (WT) or mutant-type (MT) miR-34a-5p binding sites. miR-34a-5p suppressed the expression of the reporter gene containing the 3'UTR of Snail-WT but not the 3'UTR of Snail-MT, as determined through a luciferase activity (Fig. 4G). These results suggest that TBZ-induced miR-34a-5p binds directly to the Snail 3'UTR and suppresses Snail expression. miR-34a-5p expression levels were higher in parental cells than in radioresistant CRC cells (Fig. 4H). In organoids derived from patients with radioresistant CRC, we also found that TBZ treatment increased the level of miR-34a-5p (Fig. 4I). Additionally, the expression of miR-34a-5p was higher in organoids derived from patients with radiosensitive CRC than in those from patients with radioresistant CRC (Fig. 4J). In analyses of clinical samples, we found that miR-34a-5p levels in the plasma or tissues of patients with CRC were lower than those in the normal group (Fig. 4K-L). In addition, the expression of miR-34a in various cancer types was positively correlated with the survival rate (Fig. S5). When we compared miR-34a-5p levels in the plasma of mice treated with or without TBZ, we found that the expression of miR-34a-5p was higher in the TBZ-treated group (Fig. S6). These results demonstrate that miR-34a-5p induced by TBZ treatment is associated with a good prognosis in patients with CRC. TBZ-induced miR-34a-5p attenuates tumorigenicity in radioresistant CRC We confirmed that the expression levels of EMT-related marker proteins, cell motility, and invasiveness were higher in HCT116R and SW480R cells than in parental cells but decreased upon the overexpression of miR-34a-5p (Fig. 5A-C). To elucidate the effects of TBZ and miR-34a-5p on tumorigenic potential, the two radioresistant CRC cell lines were treated with anti-miR-34a-5p with or without TBZ. In the group treated with anti-miR-34a-5p alone, EMT-related marker protein expression, cell mobility, and invasiveness were higher than those in the control group. In the group treated with TBZ alone, all tumorigenic phenotypes decreased; however, these decreases were attenuated in the group treated with TBZ combined with anti-miR-34a-5p (Fig. 5D-F). TBZ-induced miR-34a-5p reduces tumorigenic potential in radioresistant CRC cells. A-C After transfecting HCT116R and SW480R cells with miR-34a-5p mimic, the expression of EMT-related proteins (A), migratory ability (B), and invasiveness (C) were confirmed through western blotting analysis, transwell migration assay, and invasion assay, respectively (Scale bar, 100 µm). D-F After treatment with TBZ (75 µM) and transfection with anti-miR-34a-5p combinations in HCT116R and SW480R cells, the expression of EMT-related proteins (D), cell mobility (E), and invasiveness (F) were confirmed by western blotting analysis, transwell migration assay, and invasion assay respectively (Scale bar, 100 µm). β-Actin was used as a loading control. G-H After treatment with TBZ (75 µM) alone or miR-34a-5p inhibitor in RR organoids, cell viability (G) or EMT-related mRNA levels (H) were evaluated by MTT assay and qRT-PCR, respectively. qRT-PCR values were normalized by GAPDH. The data are presented as the mean ± SD after triplicate experiments. *P < 0.05, **P < 0.005, and ***P < 0.0005. Student’s t-test or ANOVA The relationship between TBZ and miR-34a-5p was confirmed in organoids derived from tumors of patients with radioresistant CRC. The TBZ-induced decreases in the survival rate of organoids and mRNA expression levels of EMT factors were attenuated by anti-miR-34a-5p overexpression (Fig. 5G-H). These results obtained using CRC cells and organoids suggest that TBZ-induced miR-34a-5p acts as a tumor suppressor. TBZ-induced p53 promotes the expression of miR-34a-5p by directly binding to the miR-34a promoter The mechanism by which TBZ-induced miR-34a-5p was analyzed in more detail. Studies have shown that p53 can induce the expression of miR-34a-5p [24]. We confirmed that p53 protein expression increased in both HCT116 and SW480 cells after TBZ treatment (Fig. 6A). We further verified that the primary, precursor, and mature forms of miR-34a-5p were reduced in HCT116 and SW480 cells in which p53 was knocked down (Fig. 6B-C). We identified a previously reported putative p53-binding site in the miR-34a promoter [24], supporting the possibility that miR-34a binds to p53 (Fig. 6D). To confirm the direct binding, we confirmed that p53 bound to the binding site of the miR-34a promoter through a chromatin immunoprecipitation (ChIP) analysis (Fig. 6E). Using WT or MT constructs of the miR-34a promoter, we verified that p53 increases luciferase activity by directly binding to the miR-34a promoter (Fig. 6F). To confirm whether TBZ-induced p53 directly regulates the expression of miR-34a-5p, cells with and without p53 knockdown were evaluated. The TBZ-induced increase in miR-34a-5p expression was reduced by the knockdown of p53 (Fig. 6G). The direct binding between p53 and the miR-34a promoter increased upon TBZ treatment, as determined using a ChIP assay (Fig. 6H). In addition, a luciferase analysis showed that the activity of the miR-34a promoter, which binds to p53, increased only in WT treated with TBZ and not in MT (Fig. 6I). In summary, these results suggest that p53 induced by TBZ treatment increases the expression of miR-34a-5p through direct binding with the miR-34a promoter and thus suppresses the tumorigenicity. TBZ transcriptionally enhances miR-34a-5p expression by inducing p53 expression. A After treating HCT116 and SW480 cells with TBZ (75 µM), p53 protein expression was confirmed by western blotting analysis. β-Actin was used as a loading control. B-C The expression of primary, precursor, and mature forms of miR-34a-5p was confirmed by qRT-PCR in HCT116 (B) and SW480 (C) cells with p53 knockdown. qRT-PCR values were normalized by GAPDH. D The putative binding motif of p53 in the promoter of miR-34a was depicted schematically. The sequences of WT and MT of the TP53 binding site in the miR-34a promoter are shown, respectively. E After overexpression of p53 protein, binding of p53 protein to the miR-34a promoter was confirmed by ChIP analysis. F The binding activity of the two factors was measured by promoter luciferase assay using WT or MT of the p53 and miR-34a promoter binding region. G Expression of miR-34a-5p was confirmed by PCR after TBZ treatment with or without P53 knockdown in HCT116 and SW480. H After TBZ treatment, the binding of p53 protein to miR-34a promoter was confirmed by ChIP assay. I Promoter luciferase assay was performed to measure the miR-34a promoter activity that binds p53 protein after TBZ treatment. The data are presented as the mean ± SD after triplicate experiments. *P < 0.05, **P < 0.005, and ***P < 0.0005. Student’s t-test or ANOVA miR-34a-5p from CRC cells reduced M2 polarization and IL-10 secretion in macrophage It is increasingly recognized that the interaction between tumors and TME is one of the major mechanisms underlying cancer malignancy. In particular, macrophages in the TME are polarized into M2-like macrophages and contribute to cancer malignancy through communication with cancer cells [37, 38]. miRNAs can move from tumor cells to macrophages, and miR-34a-5p is known to promote M1 polarization [39, 40]. In this study, we evaluated the mechanisms underlying the anticancer effects of TBZ through analyses of M2 polarization and the secretion of the major cytokine IL-10. First, we confirmed that the expression level of miR-34a-5p was higher in THP-1-derived macrophages treated with conditioned medium (CM) from HCT116R and SW480R cells overexpressing miR-34a-5p than in the control group (Fig. 7A). These results shows that CRC cells-derived miR-34a-5p was translocated to THP-1-derived macrophages. miR-34a-5p translocated from CRC cells to THP-1-derived macrophages decreased the expression of the M2 markers (CD11b, CD163, and CD206) and IL-10 compared with levels in the control group (Fig. 7B-C). The same results were obtained when miR-34a-5p was directly overexpressed in THP-1-derived macrophages (Fig. 7D). Since IL-10 is a well-established cytokine secreted by M2 macrophages [41–43], we confirmed its association with miR-34a-5p. CRC-derived miR-34a-5p reduced M2 polarization and IL-10 secretion in macrophage. A-C Conditioned media (CM) obtained after transfecting HCT116R and SW480R cells with NC and miR-34a-5p were incubated with THP-1-derived macrophages, respectively. A The expression level of miR-34a-5p was confirmed by qRT-PCR. The expression levels of M2 markers (CD11b, CD163, and CD206) and IL-10 mRNA (B-C) were confirmed by qRT-PCR, respectively. D After direct transfection of miR-34a-5p into THP-1-derived macrophages, the expression levels of M2 markers (CD11b, CD163, and CD206) and IL-10 mRNA were reconfirmed through qRT-PCR. E After TBZ treatment in THP-1-derived macrophages, the expression of miR-34a-5p was confirmed through qRT-PCR. F IL-10 secretion levels in THP-1-derived macrophages treated with TBZ were confirmed by ELISA analysis. G After co-treatment of THP-1-derived macrophages with TBZ and anti-miR-34a-5p, the effects on the expression levels of M2 markers and IL-10 mRNA were confirmed using qRT-PCR. H-J The expression of CD11b, CD206, and IL-10 in primary tumor tissues of TBZ-treated mice were compared by IHC. K CD206 expression in tissues from patients with and without radiotherapy was compared by IHC (scale bar, 100 µm). miRNA qRT-PCR values were normalized to U6, and cDNA qRT-PCR values were normalized to GAPDH. Data were expressed as mean ± standard deviation after three replicate experiments. *P < 0.05, **P < 0.005, and ***P < 0.0005. Student’s t-test or ANOVA When THP-1-derived macrophages were directly treated with TBZ, miR-34a-5p expression increased (Fig. 7E). In addition, we confirmed the expression of IL-10 through ELISA under the same conditions described above (Fig. 7F), supporting the results shown in Fig. 7B and C. Co-treatment of THP-1-derived macrophages with TBZ and anti-miR-34a-5p confirmed that the TBZ-induced decreases in M2 markers and IL-10 mRNA expression were attenuated by anti-miR-34a-5p (Fig. 7G). To determine whether TBZ is involved in inducing M2 polarization in vivo, we analyzed the expression levels of CD11b, CD206, and IL-10 in primary tumor tissues from mice using immunohistochemistry (IHC). Compared with levels in the control group, the expression levels of CD11b, CD206, and IL-10 were significantly lower in tumors from TBZ-treated mice, supporting the results of cell-based invitro assays (Fig. 7H-J). For clinical validation, we analyzed tissues of patients with CRC with and without radiotherapy revealing the expression of the M2 marker CD206 was higher in patients who received radiotherapy than in those who did not receive radiotherapy (Fig. 7K). In summary, our results suggest that TBZ-induced miR-34a-5p ultimately contributes to the inhibition of cancer malignancy by suppressing M2 polarization and IL-10 secretion through the interaction between radioresistant CRC cells and the TME. CRC-derived miR-34a-5p suppresses M2 macrophage polarization and IL-10 secretion by suppressing KLF4, ultimately reducing the tumorigenicity of CRC We evaluated the effect of miR-34a-5p translocated from CRC cells to macrophages on M2 polarization. Previous reports have shown that miR-34a-5p in macrophages suppresses the expression of KLF4, thereby reducing M2 polarization [40, 44]. According to miRDB (http://www.mirdb.org) and TargetScan (http://www.targetscan.org), sites for miRNA targets prediction, KLF4 was a predicted target of miR-34a-5p. Overexpressing miR-34a-5p in THP-1-derived macrophages suppressed KLF4 protein expression (Fig. 8A). In addition, to confirm whether KLF4 directly binds miR-34a-5p, we constructed a 3'UTR reporter plasmid containing the WT or MT miR-34a-5p binding site of the KLF4 3'UTR. miR-34a-5p suppressed the expression of the reporter gene containing the KLF4-WT 3'UTR, while it did not suppress the expression of the reporter gene containing the KLF4-MT 3'UTR, as confirmed by luciferase assays (Fig. 8B). The effects of miR-34a-5p and KLF4 on the expression of M2 markers and IL-10 mRNA in THP-1-derived macrophages were verified. When miR-34a-5p and KLF4 were overexpressed simultaneously in THP-1-derived macrophages, the miR-34a-5p-induced decreases in expression levels of M2 markers and IL-10 mRNA were restored (Fig. 8C). Analyses of IL-10 levels through ELISA yielded similar results to those for IL-10 mRNA (Fig. 8D). miR-34a-5p reduces the malignancy of CRC by suppressing M2 polarization and IL-10 secretion in macrophages by inhibiting KLF4. A The expression level of target KLF4 protein was determined by western blotting analysis after transfection of THP-1-derived macrophages with miR-34a-5p. β-Actin was used as a loading control. B To verify that KLF4 is a direct target of miR-34a-5p, firefly luciferase constructs containing wild-type (WT) or mutant-type (MT) regions of the 3'UTR of KLF4 predicted to bind miR-34a-5p were co-transfected, and the binding of the two factors was confirmed by luciferase assay. C-D The effects of co-overexpression of miR-34a-5p or KLF4 in THP-1-derived macrophages on M2 polarization and IL-10 expression were confirmed. C The expression of M2 markers (CD11b, CD163, and CD206) and IL-10 were confirmed by qRT-PCR. D The IL-10 levels in the culture medium of THP-1-derived macrophages overexpressing miR-34a-5p and KLF4 were confirmed by ELISA. E–G After treating THP-1-derived macrophages with human recombinant IL-10, CM was collected and treated with HCT116R and SW480R cells, respectively. The expression of EMT-related proteins (E), cell mobility (F), and invasiveness (G) were confirmed by western blotting analysis, transwell migration assay, and invasion assay, respectively (Scale bar, 100 µm). β-Actin was used as a loading control. cDNA qRT-PCR results were normalized to GAPDH. Data are expressed as the mean ± standard deviation after three repeated experiments. *P < 0.05, **P < 0.005, and ***P < 0.0005. Student’s t-test or ANOVA To determine the effect of IL-10 secretion from macrophages on radioresistant CRC, human recombinant IL-10 was used to treat THP-1-derived macrophages, and the collected CM was used to treat HCT116R and SW480R cells. Levels of EMT-related marker expression, cell migration, and invasive characteristics were higher in the IL-10 CM group than in the control group in both cell types (Fig. 8E-G). These results show that IL-10 secreted from macrophages is involved in the malignancy of CRC. The results of this study showed that the p53-miR-34a-5p axis induced by TBZ reduces tumor formation by suppressing the expression of Snail. In addition, miR-34a-5p secreted from CRC cells negatively affected the malignancy of radioresistant CRC by suppressing KLF4 and reducing M2 polarization and IL-10 secretion. In summary, TBZ induces the expression of miR-34a-5p, providing insight into the mechanism underlying radioresistance in CRC, including the roles of interactions between CRC cells and macrophages in the TME. These results provide basis for drug repurposing using TBZ (Fig. 9). Schematic diagram of the study highlighting the mechanism by which TBZ inhibits the tumorigenicity of radioresistant CRC through regulating the p53-miR-34a-5p/Snail axis and suppressing M2 polarization of macrophages Discussion Radiotherapy is one of the most effective methods for cancer treatment, with significant advances in radiation-based cancer therapy over the past several decades. However, the acquisition of radioresistance in cancer cells remains a major obstacle. Acquired radioresistance promotes uncontrolled cell growth, inhibits apoptosis, and induces changes in the TME, including CAFs and immune components, leading to treatment failure [45, 46]. Despite extensive research, effective strategies to overcome radioresistance are lacking. In particular, the efficacy of radiotherapy in patients with radioresistant CRC is minimal [47–49], making the development of alternative therapies crucial. To address this gap, this study aimed to elucidate the therapeutic potential of TBZ, an FDA-approved drug, in radioresistant CRC and to determine its antitumor mechanism. We confirmed that TBZ suppresses radioresistant CRC via the p53-miR-34a-5p-Snail axis within tumors and the miR-34a-5p-IL-10 axis within macrophages. Furthermore, TBZ effectively reduced organoid survival in both RS and RR PDO models. Because the PDO model exhibited characteristics highly similar to those of the original patient tumor [50], the results obtained using the PDO model provide strong preliminary evidence supporting the clinical relevance of TBZ. miR-34a-5p acts as a tumor suppressor in radioresistant CRC by targeting oncogenic factors, such as Snail and KLF4 (Figs. 4 and 8). Previous studies have identified various targets of miR-34a-5p, including Flotillin 2 (FLOT2) and SMAD4, which suppress proliferation, SIRT1, which reverses multidrug resistance, and YY1, which suppresses invasion and metastasis [51–54]. This multifaceted regulatory network involving miR-34a-5p highlights its broad tumor-suppressive function and supports the value of TBZ-induced miR-34a-5p upregulation as a promising strategy to overcome radioresistance in CRC. In radioresistant CRC cells, TBZ demonstrated a significantly greater efficacy than that of 5-FU (Fig. 2), further supporting its potential as a promising alternative for the treatment of radioresistant CRC. As 5-FU resistance and radioresistance have synergistic effects and worsen patient prognosis [55, 56], the development of novel anticancer agents for patients with radioresistant CRC is essential. In this context, the superior anticancer efficacy of TBZ, which acts independently of the established 5-FU mechanism of action, provides a foundation for further analyses of TBZ as a potential therapeutic candidate for tumors refractory to 5-FU therapy. However, further mechanistic studies are required. Radioresistance in CRC, a highly prevalent cancer, poses a major clinical challenge [3]. The results of this study suggest that TBZ can effectively overcome this hurdle and may show better efficacy than that of 5-FU. Specifically, we demonstrate that TBZ enhances radiosensitivity in CRC cells significantly. At the cellular level, co-administration of TBZ and radiation reduced cell viability significantly in radioresistant CRC cells (Fig. S3A). Furthermore, this combination effectively suppressed key malignant phenotypes, including EMT markers, cell migration, and invasiveness (Fig. S3B-D). This functional efficacy was also demonstrated in vivo, where TBZ significantly reduced tumor growth when administered in combination with radiation therapy (Fig. S3E). Collectively, our results demonstrate that TBZ effectively enhances radiosensitivity and suppresses tumor growth, highlighting its important clinical relevance in overcoming complex treatment resistance. In this study, the TBZ concentrations used in cellular-level experiments did not exhibit cytotoxicity, while maintaining cell viability, allowing tumorigenicity to be assessed. Furthermore, the TBZ concentrations administered to the animal models were intermediate doses that were well tolerated without systemic toxicity (Fig. 1H). In the future, local delivery methods, such as liposomal systems or PLGA core-lipid shell hybrid nanocarriers, should be considered to minimize potential central nervous system-related side effects in clinical settings [57, 58]. Applying these delivery systems to TBZ could support its clinical translation into a multifunctional anticancer agent that improves therapeutic efficacy in radioresistant CRC. Conclusions This study revealed the mechanism by which TBZ, an FDA-approved drug, resulted in greater reductions in the mobility and invasiveness of radioresistant CRC cells than those of 5-FU, a widely used drug for CRC. When TBZ was used to treat radioresistant HCT116R and SW480R cells, p53 binding to the miR-34a promoter increased, thereby increasing miR-34a-5p expression levels. In radioresistant CRC cells, the TBZ-induced increase in miR-34a-5p suppressed the expression of its direct target, Snail, thereby reducing cancer malignancy, inhibiting M2 macrophage polarization in the TME, and reducing IL-10 levels. Ultimately, the decreased IL-10 contributes to the suppression of the tumorigenicity of HCT116R and SW480R cells. In summary, TBZ shows promising potential as an anticancer agent in radioresistant CRC. Supplementary Information Supplementary Material 1: Table 1. Antibodies used in this study. Table 2. Primers used in this study. Supplementary Material 2. Acknowledgements Not applicable. Abbreviations Locally advanced rectal cancer Neoadjuvant chemoradiotherapy Short-course radiotherapy Vesicular monoamine transporter 2 Food and Drug Administration MicroRNA Pateint-dervied tumor organoid Radiosensitive Radioresistant Reactive oxygen species Epithelial mesenchymal transition Tetrabenazine 5-Fluorouracil Ionizing radiation Parental Resistant Kaplan–meier plot Complementary DNA Colorectal cancer Fetal bovine serum Polyvinylidene fluoride Quantitative real-time PCR 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chromatin immunoprecipitation Wild-type Mutant-type Cancer stem cells Tumor microenvironment Conditioned media Cancer associated fibroblasts Authors’ contributions I.H.B. supervised all studies. I.H.B. and D.H.L. designed the study and drafted the manuscript. D.H.L., H.J.S., and J.Y.C. participated in the animal experiments. J.H.K. and U.S.S. provided organoid and analyzed the data. All authors discussed the data and commented on the manuscript. Funding This study was conducted with support from the Ministry of Science and ICT (MSIT), the National Research Foundation of Korea, and the Korea Institute of Radiological and Medical Sciences (KIRAMS) [NRF-2021R1A2C2005966(50698–2023) and 50531–2026]. Data availability Kaplan-Meier analyses of survival in cancers were performed by the open sources KM Plotter (http://www.kmplot.com). MiRNA target prediction was provided by miRDB (http://www.mirdb.org) and TargetScan (http://www.targetscan.org). Declarations Ethics approval and consent to participate The tissues and plasma of CRC patients were Institutional Review Board (IRB) approved in Korea Institute of Radiological and Medical Sciences (KIRAMS-2021–04-002–001). Animal experiment was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Korea Institute of Radiological & Medical Sciences (Kirams2023-0134). Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1: Table 1. Antibodies used in this study. Table 2. Primers used in this study. Supplementary Material 2. Data Availability Statement Kaplan-Meier analyses of survival in cancers were performed by the open sources KM Plotter (http://www.kmplot.com). MiRNA target prediction was provided by miRDB (http://www.mirdb.org), miRmap (https://mirmap.ezlab.org) and TargetScan (http://www.targetscan.org). Kaplan-Meier analyses of survival in cancers were performed by the open sources KM Plotter (http://www.kmplot.com). MiRNA target prediction was provided by miRDB (http://www.mirdb.org) and TargetScan (http://www.targetscan.org).